Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 2/20 | 0.40 |
| ▸ | KLKB1 | P03952 | 12/20 | 0.40 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2818650 | 0.85 | PPARA (0.44) | TBXAS1KLKB1DGAT1 | |
| SCHEMBL2823043 | 0.81 | PTGER4 (0.38) | TBXAS1DGAT1HTT | |
| SCHEMBL2819674 | 0.81 | TBXAS1 (0.43) | TBXAS1KLKB1HTTTSHRPOLB | |
| SCHEMBL2819631 | 0.80 | POLB (0.51) | TBXAS1TSHRPOLBL3MBTL1 | |
| SCHEMBL2822440 | 0.76 | TBXAS1 (0.41) | TBXAS1HTTSMN1; SMN2 | |
| SCHEMBL2821382 | 0.76 | ALOX5 (0.47) | TBXAS1POLBL3MBTL1 | |
| SCHEMBL2820647 | 0.75 | ALOX5 (0.48) | TBXAS1POLBL3MBTL1 | |
| SCHEMBL2821247 | 0.75 | HDAC1 (0.46) | TBXAS1POLBL3MBTL1 | |
| SCHEMBL2822704 | 0.75 | PPARA (0.43) | TBXAS1 | |
| SCHEMBL2819380 | 0.75 | PPARA (0.51) | TBXAS1HTTTSHRPOLBL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100184815-A1 | AGONISTS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR-ALPHA | MPM ASSET MANAGEMENT INVESTORS 2002 BVIII LLC | 2010-07-22 | — | — | US | claimed |
| WO-2010071813-A1 | AGONISTS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR-α | ARYX THERAPEUTICS, INC. (US) | 2010-06-24 | — | — | WO | claimed |
| US-20100184815-A1 | AGONISTS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR-ALPHA | MPM ASSET MANAGEMENT INVESTORS 2002 BVIII LLC | 2010-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184815-A1 | AGONISTS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR-ALPHA | PPARA, PPARD, PPARG | TBXAS1 444/4885KLKB1 1854/4885DGAT1 379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.